The World Health Organization identified schizophrenia as one of the world’s 20 leading causes of disability. The presentation covers the impact of schizophrenia on patients and their caregivers, and its prevalence across different global regions. This slide deck explores the epidemiology and burden of schizophrenia and includes illustrations of the economic burden of the illness.

This slide deck has been developed in collaboration with the former Lundbeck International Neuroscience Foundation.

Index for
slide deck

Title

Epidemiology and Burden
Epidemiology and Burden
file_download Download slide in HQ

Epidemiology and Burden

Global Impact of Schizophrenia
Global Impact of Schizophrenia

The World Health Organization identified schizophrenia as 1 of the 20 leading causes of disability in the world in 2004.[The global burden of disease, 2004]

The same report estimated that the worldwide prevalence was more than 21 million people in 2016.[WHO, 2016]

Estimat…

file_download Download slide in HQ
The morbid risk of schizophrenia increases in relation to the percentage of genes shared with an affected individual
The morbid risk of schizophrenia increases in relation to the percentage of genes shared with an affected individual
file_download Download slide in HQ
The negative impact of schizophrenia on patients and their caregivers affects many aspects of life
The negative impact of schizophrenia on patients and their caregivers affects many aspects of life

Key message: Schizophrenia negatively impacts many different aspects of the lives of both patients and their caregivers (e.g. economic, physical health, social aspects).

Background

  • A community survey that included 697 caregivers and 439 patients with schizophrenia ident…

file_download Download slide in HQ
Caregivers of patients with schizophrenia can experience negative changes in their own quality of life
Caregivers of patients with schizophrenia can experience negative changes in their own quality of life

Key message: Decreases in the quality of life of caregivers may be associated with the burden of being a caregiver, lack of social support, course of the disease, and problems with family relationships.

Background[Caqueo-Urízar et al., 2009]

  • Literature review of 37 studi…
file_download Download slide in HQ
Inability to function in everyday settings contributes to the high cost of schizophrenia
Inability to function in everyday settings contributes to the high cost of schizophrenia

Key message: Inability of patients to function in everyday settings contributes to the high cost of schizophrenia (both direct costs from caring for patients, and indirect costs from lost employment).

Background

  • Schizophrenia causes a high degree of disability. In the g…
file_download Download slide in HQ
Schizophrenia One-Year Incidence Rates From Selected World Studies
Schizophrenia One-Year Incidence Rates From Selected World Studies

Review as stated on slide

file_download Download slide in HQ
Epidemiology of Schizophrenia in the United States
Epidemiology of Schizophrenia in the United States

The 1-year prevalence of schizophrenia in the United States was estimated to be 1.1% of the adult population.[Regier et al., 1993]

37 Population-based studies from 25 countries that reported primary data on deaths in people with schizophrenia were examined.[Saha et al., 2…

file_download Download slide in HQ
Prevalence of Schizophrenia in Asia
Prevalence of Schizophrenia in Asia

Taiwan: A random population of subjects from the National Health Insurance database was used to identify members with ≥1 claim for a principal diagnosis of schizophrenia.[Chien et al., 2004]

China: A random population of subjects from Xinjin County were interviewed face t…

file_download Download slide in HQ
Epidemiology of Schizophrenia in Europe
Epidemiology of Schizophrenia in Europe

Review as stated on slide

file_download Download slide in HQ
Epidemiology of Schizophrenia in Canada
Epidemiology of Schizophrenia in Canada

Vanasse and colleagues examined the lifetime prevalence of patients with schizophrenia in Quebec from 1996 to 2006 using public health plan databases. Patients were identified with a hospital discharge or physician claim for schizophrenia.[Vanasse et al., 2012]

Goldner et…

file_download Download slide in HQ

Related content

Novel and emerging pharmacologic treatments for Schizophrenia play_circle Video play_circle
Novel and emerging pharmacologic treatments for Schizophrenia

In this video Professor Christoph Correll discusses the challenges with available schizophrenia treatments & what clinicians should keep in mind when considering the emerging treatment options for schizophrenia.

14.11.2023 Schizophrenia
image Image Summary of high-level clinical characteristics of currently approved as well as newly emerging pharmacological treatments for schizophrenia with at least one positive placebo-controlled study
Summary of high-level clinical characteristics of currently approved as well as newly emerging pharmacological treatments for schizophrenia with at least one positive placebo-controlled study

The table summarizes the high-level clinical characteristics of the existing and newly emerging pharmacological treatments for schizophrenia with at least one positive placebo-controlled trial.

14.11.2023 Schizophrenia
image Image Neurotransmitter pathways involved in current and novel mechanism-action schizophrenia treatments
Neurotransmitter pathways involved in current and novel mechanism-action schizophrenia treatments

LDT=Laterodorsal tegmental nucleus; NAc = Nucleus Accumbens; SN = Substantia Nigra; VTA = Ventral Tegmental Area.

14.11.2023 Schizophrenia